摘要
目的:对5个原研二肽基肽酶4(DPP-4)抑制剂进行可量化的客观评价,为医疗机构遴选药品提供量化参考,为临床药品选择提供依据。方法:应用《中国医疗机构药品评价与遴选快速指南(第二版)》(以下简称“指南”)的评价体系,对5个原研DPP-4抑制剂的药学特性、有效性、安全性、经济性和其他属性等5个维度进行量化打分。结果:所有纳入评价的DPP-4抑制剂的评分均>70分,依次为西格列汀79.0分、维格列汀72.8分、沙格列汀76.1分、利格列汀78.7分、阿格列汀76.9分。结论:基于指南的标准,本次评价涉及的5个原研DPP-4抑制剂的评价结论均为“保留”,强推荐。但是,本次药品评价维度较多,涉及药品在各维度均有不同的优势,各医疗机构可根据评价细则及权重,按照医疗机构特点和实际需求对评价结果进行采用。
OBJECTIVE:To quantitatively and objectively evaluate the five original dipeptidyl peptidase-4(DPP-4)inhibitors,so as to provide quantitative reference for medical institutions to select drugs and provide basis for clinical drug selection.METHODS:Following the Rapid Guide for Drug Evaluation and Selection in Medical Institutions in China(Second Edition)(hereinafter referred to as“the guideline”),quantitative scores of five DPP-4 inhibitors were performed on five dimensions:pharmaceutical characteristics,effectiveness,safety,economy,and others attributes.RESULTS:All DPP-4 inhibitors included in the evaluation had scores>70 points,in the order of sitagliptin 79.0 points,vigagliptin 72.8 points,saxagliptin 76.1 points,ligagliptin 78.7 points and alogliptin 76.9 points.CONCLUSIONS:Based on the guideline criteria,the five original DPP-4 inhibitors included in this evaluation are all“retained”and strongly recommended.However,this drug evaluation has more dimensions and the drugs involved have different advantages in each dimension.Each medical institution can adopt the evaluation results according to the evaluation rules and weights,and in accordance with the characteristics and actual needs of the medical institution.
作者
李力任
阮洁
朱柏霖
张琳
钟询龙
何关生
李晓曦
朱晓冉
刘腾
王若伦
林阳
金鹏飞
王建华
郑萍
刘世霆
董占军
李亦蕾
赵志刚
LI Liren;RUAN Jie;ZHU Bolin;ZHANG Lin;ZHONG Xunlong;HE Guansheng;LI Xiaoxi;ZHU Xiaoran;LIU Teng;WANG Ruolun;LIN Yang;JIN Pengfei;WANG Jianhua;ZHENG Ping;LIU Shiting;DONG Zhanjun;LI Yilei;ZHAO Zhigang(Dept.of Pharmacy,Nanfang Hospital,Southern Medical University,Clinical Pharmacy Center,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Dept.of Pharmacy,the First Affiliated Hospital of Xinjiang Medical University,Urumchi 830000,China;Dept.of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Dept.of Pharmacy,Beijing Anzhen Hospital,Capital medical University,Beijing 100029,China;Dept.of Pharmacy,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China;Dept.of Pharmacy,Peking University People’s Hospital,Beijing 100044,China;Dept.of Pharmacy,Hebei General Hospital,Hebei Key Laboratory of Clinical Pharmacy,Shijiazhuang 050051,China;Dept.of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100050,China)
出处
《中国医院用药评价与分析》
2024年第8期989-994,共6页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
二肽基肽酶4抑制剂
评价
遴选
Dipeptidyl peptidase-4 inhibitors
Evaluation
Selection
